CJC-1295 (without DAC) and TB-500 (Ac-LKKTETQ) Interaction

Synergistic
Mechanism-based 47% confidence

CJC-1295 (without DAC) and TB-500 (Ac-LKKTETQ) have a synergistic interaction with 47% confidence. CJC-1295 (without DAC) and TB-500 (Ac-LKKTETQ) work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols. These compounds primarily affect different organ systems.

Compound Profiles

CJC-1295 (without DAC)

Short-Acting Growth Hormone Releasing Hormone Analog

Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows pulsatile release versus prolonged elevation.

Half-life: 30 minutes - 2 hours Typical dose: 100-300mcg per injection growth hormone, weight loss
ghrh receptor carcinogenic riskestrogenicinsulin disruptingteratogenic
View full profile

TB-500 (Ac-LKKTETQ)

Thymosin Beta-4 Active Fragment | Healing Peptide

TB-500 contains the LKKTETQ sequence which is the actin-binding motif of full-length thymosin beta-4. This fragment shares many properties of the parent protein regarding cell proliferation, differentiation, and migration.

Half-life: Not precisely established; effects persist longer than 24 hours Typical dose: 2-2.5mg per injection healing, longevity
vegf teratogenic
View full profile

Combined Organ Load

GI Tract
low
Pituitary
low
Blood Vessels
low

Shared Safety Flags

2x 2 compounds share the teratogenic safety flag (CJC-1295 (without DAC), TB-500 (Ac-LKKTETQ)). Monitor accordingly.

Frequently Asked Questions

Can I take CJC-1295 (without DAC) with TB-500 (Ac-LKKTETQ)?

Yes, CJC-1295 (without DAC) and TB-500 (Ac-LKKTETQ) can generally be taken together. CJC-1295 (without DAC) and TB-500 (Ac-LKKTETQ) work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.

Is CJC-1295 (without DAC) and TB-500 (Ac-LKKTETQ) safe together?

Based on pharmacological analysis, this combination is considered synergistic. However, shared safety flags include: teratogenic. Monitor accordingly.

What are the interactions between CJC-1295 (without DAC) and TB-500 (Ac-LKKTETQ)?

CJC-1295 (without DAC) and TB-500 (Ac-LKKTETQ) work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols. This assessment has 47% confidence and is inferred from pharmacological mechanism analysis.

How should I time CJC-1295 (without DAC) and TB-500 (Ac-LKKTETQ)?

CJC-1295 (without DAC) has a half-life of 30 minutes - 2 hours and TB-500 (Ac-LKKTETQ) has a half-life of Not precisely established; effects persist longer than 24 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: CJC-1295 (without DAC) vs TB-500 (Ac-LKKTETQ)

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.